Cartesian Therapeutics price to sales ratio RNAC

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 6.9×; May 2025
10-year median: 11.1×
10-year range: 1.0× to 187×
Peer median: 1.4×

Cartesian Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2025, at 6.9×.

On the days it had one over the last ten years, its median was 11.1×, from 1.0× in May 2022 to 187× in Jan 2020.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	6.9×	5.4×	10.4×
2024	10.5×	2.8×	25.1×
2023	3.1×	1.5×	6.0×
2022	1.4×	1.0×	5.1×
2021	5.7×	5.0×	48.5×
2020	29.0×	22.4×	187×
2019	119×	67.5×	139×
2018	79.3×	60.8×	79.3×
2017	70.2×	27.6×	124×

Against its peers

Companies in Drug Manufacturers - General nearest Cartesian Therapeutics' size, closest first, today.

Company	Price to sales ratio
RNACCartesian Therapeutics	n/m
NATRNatures Sunshine Products	0.4×
LFVNLifevantage	0.4×
ARVNArvinas	1.5×
SPROSpero Therapeutics	1.4×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
ATNMActinium Pharmaceuticals	n/m
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Cartesian Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.